Bile acid PET/CT scan for genetic liver disorders
Part of Digestive system clinical trials.
This study uses a special PET/CT scan with a tracer called 11C-Csar, which is similar to bile acid, to see how well your liver handles bile. It is for healthy people and those with genetic liver diseases that cause cholestasis (slowed bile flow). The goal is to improve diagnosis and understanding of these conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have no known liver disease (if healthy) OR you have cholestasis (elevated ALP or bilirubin) not caused by a physical blockage (if patient).
- You do not take any medications that affect your liver or bile system (if healthy).
- You are not pregnant and can have a negative pregnancy test on scan day.
- You do not have claustrophobia and can lie still for 45 minutes.
- You have not had your gallbladder removed (cholecystectomy).
- You are willing and able to give signed consent on the scan day.
- You do not have a blood clotting problem that would prevent a liver vein catheter (if patient).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares different scan types (MRI, CT, and two PET scans) in people with hepatocellular carcinoma (a primary liver cancer). It may help doctors figure out which scan gives the most useful information for diagnosis and treatment planning.
This study looks at how well special imaging scans (PET/CT or PET/MRI) work in adults with suspected or diagnosed liver cancer. It may help doctors better see the cancer and plan next steps.
This study tests whether a special PET scan (using [18F]FTT) can predict how well the standard GCD chemotherapy and immunotherapy combination will work for newly diagnosed bile duct cancer. The scan helps doctors see tumor activity before treatment.
This study uses a special MRI scan with a substance called pyruvate to see how liver cancer tumors are using energy. The goal is to find out if this scan can predict how well treatment will work and help guide future care.
This trial tests a new type of PET-CT scan (called FAPI) to see if it helps doctors better decide treatment for people with bile duct cancer that can be surgically removed. It may help avoid unnecessary surgery if the scan shows the cancer has spread.
This study uses a special PET/MRI scanner to take detailed pictures of your liver and bile ducts. It may help doctors better understand and manage PSC without any treatment or medication.
Hear when a new Cholestasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.